Index - P/E 1.55 EPS (ttm) 0.39 Insider Own 2.46% Shs Outstand 80.10M Perf Week 2.46%
Market Cap 48.76M Forward P/E - EPS next Y -0.48 Insider Trans -3.90% Shs Float 78.13M Perf Month -6.76%
Income 31.87M PEG - EPS next Q 0.06 Inst Own 58.45% Short Float 11.53% Perf Quarter -40.61%
Sales 138.10M P/S 0.35 EPS this Y -97.15% Inst Trans -9.76% Short Ratio 4.94 Perf Half Y -48.42%
Book/sh -0.01 P/B - EPS next Y -4527.74% ROA 19.44% Short Interest 9.00M Perf Year -71.69%
Cash/sh 1.26 P/C 0.48 EPS next 5Y - ROE - 52W Range 0.56 - 5.85 Perf YTD -40.90%
Dividend Est. - P/FCF - EPS past 5Y - ROI 842.20% 52W High -89.59% Beta 1.14
Dividend TTM - Quick Ratio 1.25 Sales past 5Y 36.21% Gross Margin 98.72% 52W Low 8.70% ATR (14) 0.06
Dividend Ex-Date - Current Ratio 1.25 EPS Y/Y TTM 2446.43% Oper. Margin 18.10% RSI (14) 42.51 Volatility 9.57% 9.41%
Employees 121 Debt/Eq - Sales Y/Y TTM 36.45% Profit Margin 23.08% Recom 1.83 Target Price 4.94
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q 1800.81% Payout 0.00% Rel Volume 0.50 Prev Close 0.58
Sales Surprise 192.12% EPS Surprise 212.65% Sales Q/Q 43.17% Earnings Mar 06 AMC Avg Volume 1.82M Price 0.61
SMA20 -3.37% SMA50 -16.29% SMA200 -42.22% Trades
Volume 905,988 Change 4.95%
Date
Action
Analyst
Rating Change
Price Target Change
May-28-24 Upgrade Piper Sandler
Neutral → Overweight
$2.25 → $3.50
May-09-24 Upgrade Wedbush
Neutral → Outperform
$8
May-06-24 Upgrade Jefferies
Hold → Buy
$2.50 → $8
Apr-22-24 Upgrade JP Morgan
Underweight → Neutral
Nov-14-22 Downgrade BMO Capital Markets
Outperform → Market Perform
$3 → $2.60
Jul-07-22 Downgrade Wedbush
Outperform → Neutral
$6 → $2
Jul-07-22 Downgrade Piper Sandler
Overweight → Neutral
$10 → $1.50
Jul-07-22 Downgrade Mizuho
Buy → Neutral
$16 → $4
Jul-07-22 Downgrade Jefferies
Buy → Hold
$12 → $2
Jun-24-22 Initiated BMO Capital Markets
Outperform
$9
Jan-18-22 Upgrade Barclays
Underweight → Overweight
$7
Nov-15-21 Initiated BTIG Research
Buy
$16
May-28-21 Downgrade Barclays
Equal Weight → Underweight
$9 → $7
Mar-29-21 Initiated JP Morgan
Overweight
$14
Mar-23-21 Upgrade Jefferies
Hold → Buy
Sep-22-20 Downgrade Guggenheim
Buy → Neutral
Jun-01-20 Downgrade Jefferies
Buy → Hold
$16 → $10
May-14-20 Reiterated H.C. Wainwright
Buy
$16 → $12
Mar-24-20 Upgrade Wedbush
Neutral → Outperform
Mar-04-20 Initiated Barclays
Equal Weight
$7
Show Previous Ratings
Apr-01-25 10:50AM
Mar-28-25 11:20AM
Mar-26-25 07:58AM
02:06AM
Mar-25-25 07:56AM
01:03PM
Loading…
Mar-21-25 01:03PM
01:01PM
Mar-19-25 01:38PM
Mar-11-25 12:00PM
Mar-07-25 06:45PM
07:41AM
(Thomson Reuters StreetEvents)
02:18AM
Mar-06-25 05:35PM
04:10PM
Mar-05-25 08:00AM
07:35AM
Loading…
07:35AM
Feb-27-25 08:00AM
Jan-08-25 08:00AM
Jan-07-25 12:00PM
Jan-06-25 04:05PM
Dec-16-24 09:55AM
Nov-27-24 08:00AM
Nov-19-24 09:35AM
Nov-08-24 11:54AM
(Thomson Reuters StreetEvents) +9.00%
02:32AM
Nov-07-24 05:55PM
04:49PM
(Associated Press Finance)
04:10PM
Nov-06-24 07:52AM
Oct-31-24 08:00AM
08:00AM
Loading…
Sep-09-24 08:00AM
Sep-04-24 08:00AM
Aug-10-24 08:18AM
Aug-08-24 09:56PM
05:46PM
(Associated Press Finance)
04:10PM
Aug-01-24 08:00AM
Jul-25-24 02:26AM
Jun-18-24 08:00AM
Jun-17-24 04:15PM
Jun-05-24 06:00AM
Jun-03-24 09:17AM
May-29-24 06:25AM
May-22-24 04:05PM
May-16-24 04:15PM
May-15-24 11:14AM
May-09-24 04:17PM
11:56AM
11:32AM
08:12AM
(Thomson Reuters StreetEvents)
07:48AM
07:29AM
04:01AM
May-08-24 09:58PM
04:30PM
(Associated Press Finance)
04:10PM
04:10PM
May-07-24 04:15PM
May-06-24 07:09AM
May-02-24 08:08AM
07:37AM
May-01-24 12:11PM
11:43AM
08:00AM
Apr-08-24 08:00AM
Apr-03-24 08:00AM
Mar-21-24 08:00AM
Mar-18-24 08:00AM
Mar-12-24 09:12AM
08:30AM
06:46AM
(Thomson Reuters StreetEvents)
Mar-11-24 05:34PM
05:20PM
04:10PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
08:00AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
(Associated Press Finance)
04:15PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:26PM
(Associated Press Finance)
04:15PM
Aug-01-23 08:00AM
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McCarthy Sean A. CEO Mar 18 '25 Sale 0.60 37,656 22,556 995,195 Mar 20 04:34 PM Ogden Christopher Chief Financial Officer Mar 18 '25 Sale 0.60 8,551 5,122 201,026 Mar 20 04:33 PM Chu Yu-Waye Chief Medical Officer Mar 18 '25 Sale 0.60 4,025 2,411 135,725 Mar 20 04:32 PM ROWLAND LLOYD A General Counsel Mar 18 '25 Sale 0.60 10,203 6,112 120,594 Mar 20 04:32 PM BELVIN MARCIA SVP, Chief Scientific Officer Mar 18 '25 Sale 0.60 19,512 11,688 248,636 Mar 20 04:31 PM Landau Jeffrey B Chief Business Officer Aug 20 '24 Option Exercise 0.00 11,250 0 123,237 Aug 22 06:01 PM Landau Jeffrey B Chief Business Officer Aug 20 '24 Sale 1.23 4,181 5,139 119,056 Aug 22 06:01 PM BELVIN MARCIA SVP, Chief Scientific Officer Aug 20 '24 Option Exercise 0.00 11,250 0 179,829 Aug 22 06:01 PM BELVIN MARCIA SVP, Chief Scientific Officer Aug 20 '24 Sale 1.23 4,181 5,139 175,648 Aug 22 06:01 PM ROWLAND LLOYD A General Counsel Aug 20 '24 Option Exercise 0.00 11,250 0 134,978 Aug 22 06:00 PM ROWLAND LLOYD A General Counsel Aug 20 '24 Sale 1.23 4,181 5,139 130,797 Aug 22 06:00 PM Ogden Christopher Chief Financial Officer Aug 20 '24 Option Exercise 0.00 6,875 0 110,061 Aug 22 05:59 PM Ogden Christopher Chief Financial Officer Aug 20 '24 Sale 1.23 1,984 2,439 108,077 Aug 22 05:59 PM McCarthy Sean A. CEO Aug 20 '24 Option Exercise 0.00 37,500 0 671,749 Aug 22 05:58 PM McCarthy Sean A. CEO Aug 20 '24 Sale 1.23 13,898 17,082 657,851 Aug 22 05:58 PM
Index RUT P/E - EPS (ttm) -1.65 Insider Own 9.70% Shs Outstand 113.93M Perf Week -9.85%
Market Cap 88.24M Forward P/E - EPS next Y -1.38 Insider Trans 0.32% Shs Float 103.48M Perf Month -18.95%
Income -186.26M PEG - EPS next Q -0.39 Inst Own 84.93% Short Float 14.08% Perf Quarter -52.47%
Sales 13.63M P/S 6.47 EPS this Y 5.65% Inst Trans -13.05% Short Ratio 6.37 Perf Half Y -78.00%
Book/sh 2.80 P/B 0.28 EPS next Y 10.77% ROA -39.34% Short Interest 14.57M Perf Year -89.12%
Cash/sh 2.44 P/C 0.32 EPS next 5Y 9.44% ROE -54.21% 52W Range 0.75 - 7.34 Perf YTD -53.33%
Dividend Est. - P/FCF - EPS past 5Y -2.63% ROI -46.97% 52W High -89.52% Beta 2.43
Dividend TTM - Quick Ratio 7.58 Sales past 5Y 46.37% Gross Margin -39.11% 52W Low 2.67% ATR (14) 0.09
Dividend Ex-Date - Current Ratio 7.58 EPS Y/Y TTM -0.92% Oper. Margin -1434.52% RSI (14) 33.07 Volatility 7.83% 8.91%
Employees 181 Debt/Eq 0.27 Sales Y/Y TTM -78.55% Profit Margin -1366.46% Recom 2.50 Target Price 6.59
Option/Short Yes / Yes LT Debt/Eq 0.24 EPS Q/Q 1.03% Payout - Rel Volume 1.56 Prev Close 0.76
Sales Surprise 35.44% EPS Surprise -1.73% Sales Q/Q 10.98% Earnings Mar 05 AMC Avg Volume 2.29M Price 0.77
SMA20 -15.48% SMA50 -32.46% SMA200 -70.42% Trades
Volume 3,575,974 Change 1.70%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-18-24 Upgrade BofA Securities
Underperform → Neutral
Jun-17-24 Upgrade Piper Sandler
Neutral → Overweight
$4 → $6
Mar-27-23 Resumed Wells Fargo
Equal Weight
$6
Jan-24-23 Downgrade H.C. Wainwright
Buy → Neutral
$115 → $7
Jan-06-23 Downgrade Wedbush
Outperform → Neutral
$42 → $7
Jan-06-23 Downgrade Truist
Buy → Hold
$46 → $7
Jan-06-23 Downgrade Stifel
Buy → Hold
$107 → $5.30
Jan-06-23 Downgrade Piper Sandler
Overweight → Neutral
$71 → $12
Jan-06-23 Downgrade Cowen
Outperform → Market Perform
Jan-06-23 Downgrade BofA Securities
Buy → Underperform
$72 → $4
Jan-06-23 Downgrade BMO Capital Markets
Outperform → Market Perform
$20 → $7
Jan-03-23 Downgrade Guggenheim
Buy → Neutral
Dec-22-22 Downgrade Oppenheimer
Outperform → Perform
Dec-15-22 Initiated Goldman
Sell
$10
Nov-04-22 Resumed Cantor Fitzgerald
Overweight
$98 → $45
Oct-10-22 Initiated Canaccord Genuity
Buy
$42
Aug-18-22 Resumed Wells Fargo
Overweight
$90
Jul-28-22 Initiated Needham
Hold
Jul-11-22 Upgrade BMO Capital Markets
Market Perform → Outperform
$50 → $47
Jun-03-22 Initiated Robert W. Baird
Neutral
$28
Show Previous Ratings
Apr-02-25 04:01PM
Mar-05-25 05:10PM
04:12PM
(Associated Press Finance)
04:01PM
Mar-04-25 04:01PM
10:00AM
Loading…
Feb-17-25 10:00AM
Feb-14-25 04:01PM
(GlobeNewswire) +11.81%
+7.75%
Feb-04-25 04:01PM
Jan-03-25 04:01PM
Dec-12-24 11:30AM
Dec-09-24 04:01PM
Dec-03-24 04:01PM
Dec-02-24 09:55AM
(Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM
Nov-26-24 04:01PM
(GlobeNewswire) +10.74%
+18.28%
08:05AM
Loading…
Nov-18-24 08:05AM
08:00AM
Nov-12-24 05:20PM
04:18PM
(Associated Press Finance)
04:01PM
Nov-09-24 01:30PM
Nov-08-24 04:01PM
(GlobeNewswire) -5.10%
+5.79%
Nov-04-24 04:01PM
Oct-02-24 04:01PM
Sep-12-24 04:01PM
11:30AM
Aug-16-24 12:00PM
Aug-13-24 05:25PM
04:25PM
(Associated Press Finance)
04:05PM
04:01PM
Loading…
Aug-02-24 04:01PM
(GlobeNewswire) -5.12%
-9.50%
Jul-31-24 08:00AM
Jul-21-24 05:37AM
Jul-02-24 04:01PM
Jun-04-24 04:01PM
May-29-24 04:01PM
May-13-24 10:48AM
May-10-24 02:50PM
10:36AM
08:22AM
May-09-24 08:58PM
05:25PM
04:21PM
(Associated Press Finance)
04:01PM
08:30AM
May-06-24 08:00AM
May-03-24 04:30PM
Apr-22-24 04:30PM
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
Apr-02-24 04:01PM
Mar-27-24 11:30AM
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-26-24 05:10PM
04:35PM
04:08PM
(Associated Press Finance)
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
(GlobeNewswire) +11.67%
+11.19%
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
(Associated Press Finance)
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
(Thomson Reuters StreetEvents)
Aug-08-23 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wolchko J Scott Former Officer and Director Mar 06 '25 Proposed Sale 0.93 113,178 104,881 Mar 06 01:52 PM Bressi Jerome Charles See Remarks Jan 10 '25 Sale 1.55 5,980 9,269 270,203 Jan 13 04:06 PM TAHL CINDY See Remarks Jan 10 '25 Sale 1.55 5,654 8,764 336,707 Jan 13 04:05 PM Valamehr Bahram President and CEO Jan 10 '25 Sale 1.54 8,705 13,406 349,364 Jan 13 04:04 PM Valamehr Bahram Officer Jan 10 '25 Proposed Sale 1.54 8,705 13,447 Jan 10 03:20 PM Bressi Jerome Charles Officer Jan 10 '25 Proposed Sale 1.55 5,980 9,276 Jan 10 03:12 PM TAHL CINDY Officer Jan 10 '25 Proposed Sale 1.55 5,654 8,782 Jan 10 03:12 PM Redmile Group, LLC Director Dec 20 '24 Buy 1.68 397,964 668,580 12,884,277 Dec 26 09:00 PM Redmile Group, LLC Director Dec 20 '24 Sale 1.68 341,633 573,943 12,486,313 Dec 26 09:00 PM Redmile Group, LLC Director, 10% Stockholder Dec 20 '24 Proposed Sale 1.66 341,633 567,111 Dec 20 09:00 PM Xu Yuan Director Aug 06 '24 Sale 4.23 633 2,678 8,669 Aug 07 04:01 PM Xu Yuan Director Aug 06 '24 Proposed Sale 4.23 633 2,678 Aug 06 10:34 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
